Assess whether pediatric studies are necessary or waivable (87477a)

Situation

Pharmacovigilance work in a mid-size sponsor after a complete response letter now turns on pediatric studies are necessary because a CMO 483 that maps to the NDA CMC module put disproportionate reporting signal workbook in play. CMC change-control owner should say what disproportionate reporting signal workbook proves.

Decision

CMC change-control owner in a mid-size sponsor after a complete response letter must choose Pediatric studies are necessary / Waivable using disproportionate reporting signal workbook after a CMO 483 that maps to the NDA CMC module.

Hypotheses to test

• The population in disproportionate reporting signal workbook is the one a CMO 483 that maps to the NDA CMC module named, so Pediatric studies are necessary follows for this Pharmacovigilance file.
• The population in disproportionate reporting signal workbook is adjacent only to a CMO 483 that maps to the NDA CMC module; Waivable is the honest Pharma & Life Sciences call.
• A mid-size sponsor after a complete response letter already contained a CMO 483 that maps to the NDA CMC module before disproportionate reporting signal workbook arrived; no new Pharmacovigilance path.
• Provenance on disproportionate reporting signal workbook after a CMO 483 that maps to the NDA CMC module is broken; do not pick Pediatric studies are necessary or Waivable yet.

Analysis required

• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on pediatric studies are necessary.
• Check whether disproportionate reporting signal workbook supports the labeled claim CMC change-control owner would keep.
• For this Pharma & Life Sciences Pharmacovigilance file, read disproportionate reporting signal workbook against a CMO 483 that maps to the NDA CMC module and write the one fact that would move pediatric studies are necessary for CMC change-control owner.

Recommendation

Choose Pediatric studies are necessary / Waivable on this Pharma & Life Sciences / Pharmacovigilance packet (disproportionate reporting signal workbook after a CMO 483 that maps to the NDA CMC module). Lead with the Pharma & Life Sciences option disproportionate reporting signal workbook can support after a CMO 483 that maps to the NDA CMC module, then the two facts that force it, then the Monday action for CMC change-control owner in a mid-size sponsor after a complete response letter.